Login | Register
Profile | Log out
logo

  • Home
  • News
  • Opinion
  • Other
    • Market Updates
    • Explainers
    • Satire
  • About
  • Contact Us
    • Contact
    • Get Covered
    • Posting Guidelines
  • Subscribe
Submit An Article

Latest Articles

  • Nanoveu Secures $2 Million to Fast-Track Commercial Launch of ECS-DoT Chip and AIoT Platform
    Nanoveu Secures $2 Million to Fast-Track Commercial Launch of ECS-DoT Chip and AIoT Platform
    • News

  • Archer Unlocks Cryogenic Sensor Breakthrough for Quantum Computing
    Archer Unlocks Cryogenic Sensor Breakthrough for Quantum Computing
    • News

  • EGL Secures $1.9M PFAS Plant Contract as Demand for Clean-Up Technologies Surges
    EGL Secures $1.9M PFAS Plant Contract as Demand for Clean-Up Technologies Surges
    • News

  • RocketDNA Secures Major Aerial Tech Contract with Vault Minerals at WA Gold Site
    RocketDNA Secures Major Aerial Tech Contract with Vault Minerals at WA Gold Site
    • News

  • BirdDog Boosts Buy-Back Offer by 40% Ahead of ASX Delisting Vote
    BirdDog Boosts Buy-Back Offer by 40% Ahead of ASX Delisting Vote
    • News

  • AML3D Launches High-Tech U.S. Facility to Power Submarine Supply Chain
    AML3D Launches High-Tech U.S. Facility to Power Submarine Supply Chain
    • News

  • Vection Enters $520K Agritech Deal to Build AI-Powered Farming Robot
    Vection Enters $520K Agritech Deal to Build AI-Powered Farming Robot
    • News

  • Unith Achieves Strong Growth in Platform Usage and Strategic Partnerships
    Unith Achieves Strong Growth in Platform Usage and Strategic Partnerships
    • News

  • FBR and Samsung Heavy Industries Execute Engineering Service Agreement for Shipbuilding Automation Project
    FBR and Samsung Heavy Industries Execute Engineering Service Agreement for Shipbuilding Automation Project
    • News

  • Bioxyne Lifts FY2025 Revenue Forecast as Psychedelics and Pharma Push Gains Pace
    Bioxyne Lifts FY2025 Revenue Forecast as Psychedelics and Pharma Push Gains Pace
    • News

Pharmaxis eyes cancer treatment trials in US as dosage study advances

  • In News
  • June 11, 2021
  • Alfred Chan
Pharmaxis eyes cancer treatment trials in US as dosage study advances

A new treatment for the deadly bone marrow cancer myelofibrosis is one step closer to a FDA application with clinical stage drug development company Pharmaxis (ASX: PXS) having successfully completed dosing of the first stage of its current trial.

With the first dosing of PXS-5505 confirmed as safe by the study’s safety monitoring committee, Pharmaxis will now progress to the second dose level for trial participants in Australia and South Korea. This second round of dosing is expected to take four weeks while Pharmaxis has already commenced discussions with potential trial sites in the United States in anticipation for the final round of the dose expansion study.

“PXS‐5505 has demonstrated good tolerability and very consistent pharmacokinetic properties in the first dose escalation stage of MF‐101,” said Pharmaxis CEO, Gary Phillips.

“This is very much in line with the results from our phase 1 healthy volunteer study reported last year. Further data from this first dose will be available in coming weeks but based on the pharmacokinetic profile I anticipate that we will see significant inhibition of all lysyl oxidase enzymes even at this lowest level of dose.”

Myelofibrosis – a type of bone cancer which affects 15 in every 1 million Americans. At present, current forms of treatment are classified by the US Food and Drug Administration to be limited in their effectiveness which was one reason PXS-5505 was graded Orphan Drug Designation and approved to commence their Investigative New Drug trials.

Although prevalence of myelofibrosis is rare, current forms of treatment generate more than $1 billion annually while largely masking symptoms of the disease. Comparatively, pre-clinical trials of PXS-5505 have shown the potential to modify the disease which would be a game-changing treatment for a disease that has an average life expectancy of just five years after diagnosis.

Taken orally, PXS‐5505 inhibits the lysyl oxidase family of enzymes which in turn seeks to reverse the bone marrow fibrosis that advances myelofibrosis.

Unlike many clinical stage research companies, Pharmaxis is in the enviable position of having its trials funded by cash flow from its respiratory pharmaceuticals division which already has various FDA-approved products on the market.

“We’re expecting the respiratory business division to be cash flow positive this year and for years going ahead. “In fact, if we look at five years out, we expect a positive cash flow from that business of about $10 million per annum,” said Phillips in a recent investor briefing.

While myelofibrosis remains the primary focus in the development of PXS-5505, its anti-fibrotic properties have been flagged by academics as a potential treatment for other diseases such as liver and pancreatic cancer. Additional research was confirmed last month when the Charlie Teo Foundation committed funding to explore PXS-5505’s application as a treatment for brain cancer.  

Pharmaxis welcomes investors to register for updates on their latest developments and industry research by joining their mailing list here.

 

*Owners of this website are PXS shareholders

  • About
  • Latest Posts
Alfred Chan
Alfred Chan is a Business Reporter at The Sentiment specialising in ASX-listed small cap companies, a bloodstock enthusiast and former equities analyst.
Latest posts by Alfred Chan (see all)
  • Harris Technology to expand refurbished tech division amid rising demand from cost-conscious Australians - April 30, 2025
  • Harris Technology secures major investment from Taiwan’s FSP Technology at 100% premium - March 10, 2025
  • ARC Funds acquires 30% of auzbiz Capital as latest direct-to-investor marketing venture - October 8, 2024
  •  
  •  
  •  
  •  
  • News

Leave a Comment

You must be logged in to post a comment.

  • About
  • Latest Posts
Alfred Chan
Alfred Chan is a Business Reporter at The Sentiment specialising in ASX-listed small cap companies, a bloodstock enthusiast and former equities analyst.
Latest posts by Alfred Chan (see all)
  • Harris Technology to expand refurbished tech division amid rising demand from cost-conscious Australians - April 30, 2025
  • Harris Technology secures major investment from Taiwan’s FSP Technology at 100% premium - March 10, 2025
  • ARC Funds acquires 30% of auzbiz Capital as latest direct-to-investor marketing venture - October 8, 2024

Login or register for free to access unlimited reading

Register Now!
  • About
  • Latest Posts
Alfred Chan
Alfred Chan is a Business Reporter at The Sentiment specialising in ASX-listed small cap companies, a bloodstock enthusiast and former equities analyst.
Latest posts by Alfred Chan (see all)
  • Harris Technology to expand refurbished tech division amid rising demand from cost-conscious Australians - April 30, 2025
  • Harris Technology secures major investment from Taiwan’s FSP Technology at 100% premium - March 10, 2025
  • ARC Funds acquires 30% of auzbiz Capital as latest direct-to-investor marketing venture - October 8, 2024
  • News

  • Opinion

  • Satire

  • About

  • Contact Us

  • Subscribe

The content published on this website is solely for general information purposes and is not to be construed as financial advice. Should you seek financial advice you should consult with an appropriately qualified person. Opinions expressed on this site are subject to change without notice and The Sentiment who produced this content is under no obligation to keep the information current. The Sentiment, affiliated companies & associates may have a conflict of interest with companies discussed on the website due to commercial arrangements, for example they may be shareholders in the company, be engaged by them to assist in investor communications or receive commission/brokerage for funds raised.

Copyright © 2020 The Sentiment. All rights reserved.
Subscribe

Enter your email address below to subscribe to The Sentiment’s weekly newsletter, highlighting the top news, research, opinion and satire articles shaping ASX investor sentiment.

The Sentiment respects your privacy and will not spam you. View our privacy policy here.